Cellulose sulfate - Polydex Pharmaceuticals/CONRAD

Drug Profile

Cellulose sulfate - Polydex Pharmaceuticals/CONRAD

Alternative Names: Ushercell

Latest Information Update: 03 Feb 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Polydex Pharmaceuticals
  • Developer CONRAD
  • Class Antivirals; Biopolymers; Contraceptives; Glucans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Bacterial vaginosis; Pregnancy
  • Discontinued Chlamydial infections; Gonorrhoea; HIV infections

Most Recent Events

  • 31 Jul 2012 Cellulose sulfate - Polydex Pharmaceuticals/CONRAD is available for licensing as of 31 Jul 2012. http://www.polydex.com/
  • 31 Dec 2010 Suspended - Clinical-Phase-Unknown for Pregnancy (Prevention) in Zimbabwe (Vaginal)
  • 31 Dec 2010 Suspended - Phase-I for Pregnancy (Prevention) in Dominican Republic (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top